Multi-cancer early detection
Blood tests that screen for many cancers at once.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 9, 8, 8, 5, 8.
All papers from the last 12 months
113 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Advances in Liquid Biopsy for Precision Oncology: Applications, Challenges, and Future Directions in Clinical LaboratoriesOnco Targets Ther2026PMID 42866599Review
- Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer DiagnosisN Engl J Med2026 Oct 8PMID 42776074RCT
- Projected impact of population-level multi-cancer early detection screening: a discrete event simulation analysisJ Natl Cancer Inst2026 Oct 6PMID 42836653
- Multi-Cancer Early Detection Tests and Prostate Cancer Screening: Navigating the GapsJ Urol2026 Oct 5PMID 42832818
- Performance of a multi-biomarker class, multi-cancer early detection (MCED) blood test in a prospectively collected cohortCancer Epidemiol Biomarkers Prev2026 Oct 2PMID 42826075
- Study raises important questions about the clinical utility of multicancer early detection testing: Trial shows that testing increased early-stage cancer detection but did not significantly reduce late-stage diagnosesCancer2026 Oct 1PMID 42806912
- Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation-The Peachtree ConsensusCancer2026 Oct 1PMID 42775648
- Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trialNat Med2026 OctPMID 42773209RCT
- Some answers, more questions for multi-cancer early detection testsNat Med2026 OctPMID 42773208
- Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 studyNat Med2026 OctPMID 42773207
More oncology trends
All specialties →Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
CDK4/6 inhibitors in breast cancer
Palbociclib, ribociclib and abemaciclib in hormone receptor-positive breast cancer.
Radioligand therapy
Radioactive drugs that target tumour receptors, such as lutetium-177 PSMA.
Key point: Most international guidelines endorse 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer after prior ARPI and taxane chemotherapy.
KRAS inhibitors
Drugs targeting KRAS mutations, such as sotorasib and adagrasib.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"multi-cancer early detection"[tiab] OR "multicancer early detection"[tiab] OR MCED[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.